Capital Performance Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.6M Sell
6,284
-3,811
-38% -$888K 0.1% 91
2026
Q1
$2.47M Buy
10,095
+871
+9% +$203K 0.17% 64
2025
Q4
$1.91M Buy
9,224
+4,517
+96% +$893K 0.14% 74
2025
Q3
$873K Sell
4,707
-65
-1% -$11.1K 0.14% 79
2025
Q2
$729K Sell
4,772
-3,087
-39% -$475K 0.14% 76
2025
Q1
$1.3M Buy
+7,859
New +$1.23M 0.29% 51
2024
Q4
Sell
-1,961
Closed -$318K 1439
2024
Q3
$318K Buy
+1,961
New +$312K 0.1% 73

Other funds holding JNJ

Capital Performance Advisors's JNJ Position: Q2 2026 in Review

Capital Performance Advisors reduced its Johnson & Johnson (JNJ) stake by 38% in Q2 2026, selling an estimated $888K and leaving 6,284 shares worth $1.6M. The position accounts for 0.1% of the portfolio, ranked #91.

Capital Performance Advisors first reported a position in JNJ in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.47M in Q1 2026. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Capital Performance Advisors held 6,284 shares of Johnson & Johnson worth $1.6M as of Q2 2026.
  • Capital Performance Advisors sold 3,811 Johnson & Johnson shares in Q2 2026, an estimated $888K.
  • Johnson & Johnson made up 0.1% of Capital Performance Advisors's portfolio in Q2 2026, its #91 holding.
  • Capital Performance Advisors first reported a position in Johnson & Johnson in Q3 2024 and has held it in 7 quarters since.
  • Capital Performance Advisors's Johnson & Johnson position peaked at $2.47M in Q1 2026.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.